Advancing Drug Development in Myelodysplastic Syndromes

Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the United States Food and Drug Administration (FDA), (e.g., lu...

Full description

Saved in:
Bibliographic Details
Published in:Blood advances 2024-12
Main Authors: Mina, Alain, McGraw, Kathy L., Cunningham, Lea, Kim, Nina, Jen, Emily Y, Calvo, Katherine R, Ehrlich, Lori A., Aplan, Peter D., Garcia-Manero, Guillermo, Foran, James M, Garcia, Jacqueline S., Zeidan, Amer M., DeZern, Amy E., Komrokji, Rami S., Sekeres, Mikkael A., Scott, Bart L, Buckstein, Rena J., Tinsley-Vance, Sara, Verma, Amit, Wroblewski, Tanya, Pavletic, Steven Z, Norsworthy, Kelly J
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the United States Food and Drug Administration (FDA), (e.g., luspatercept, ivosidenib, decitabine/cedazuridine and imetelstat), there has been little progress in the development of truly transformative therapies for the treatment of patients with MDS. Challenges to advancing drug development in MDS are multifold but may be grouped into specific categories including criteria for risk stratification and eligibility, response definitions, time-to-event endpoints, transfusion endpoints, functional assessments, and biomarker development. Strategies to address these challenges and optimize future clinical trial design for patients with MDS are presented here.
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2024014865